2511 — HighTide Therapeutics Income Statement
0.000.00%
Last trade - 00:00- HK$2.05bn
- HK$1.68bn
Annual income statement for HighTide Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 217 | 190 | 939 | 380 | 230 |
| Operating Profit | -217 | -190 | -939 | -380 | -230 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -221 | -190 | -939 | -382 | -232 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -221 | -190 | -939 | -382 | -232 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -221 | -190 | -939 | -382 | -245 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -221 | -190 | -939 | -382 | -245 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.459 | -0.397 | -1.94 | -0.844 | -0.511 |